Core Viewpoint - The 2025 Changchun Airshow marks a significant moment in China's aviation history, showcasing a variety of aircraft and attracting millions of attendees both on-site and online [1][11]. Group 1: Event Overview - The Changchun Airshow has seen a steady increase in attendance, with figures rising from 500,000 in 2019 to 996,000 in 2025 [1]. - The event has evolved significantly, with the 2023 airshow featuring 140 participating enterprises and over 1,000 exhibits, doubling the number from the previous year [10]. - The 2025 airshow will utilize the Changchun International Aviation Expo City, covering an area of 2.358 million square meters, which is equivalent to 330 standard football fields [11]. Group 2: Historical Context and Development - The first Changchun Airshow was held in October 2019, with only 77 days of preparation, and it attracted 500,000 visitors [8][9]. - The second airshow in 2021 saw a significant expansion, with 180 civil aircraft on display, nearly tripling the number from the first event [10]. - The airshow has become a symbol of Changchun's growing reputation in the aviation industry, often compared to the established Zhuhai Airshow [10]. Group 3: Economic and Industrial Impact - The airshow has catalyzed the development of related industries in Changchun, including optics, new materials, and information technology, aligning with the "exhibition-driven production" strategy [3][4]. - The local government has initiated plans to develop the low-altitude economy, aiming for a scale of 3 billion yuan by 2026, with over 30 enterprises in the sector [15][16]. - Changchun's aerospace industry is experiencing rapid growth, with numerous leading enterprises and a robust supply chain contributing to a strong industrial cluster [15]. Group 4: Community Engagement and Cultural Significance - The airshow has fostered a sense of community involvement, with local transportation and security services mobilizing extensive resources to ensure a smooth experience for attendees [14]. - The event has become a platform for national pride and education, igniting interest in military aviation and patriotism among the public [17]. - The Changchun Airshow is seen as a window to showcase the city's openness and progress, enhancing its attractiveness for future collaborations and investments [14].

深圳河套学院执行院长罗智泉院士指出，河套合作区作为以科技创新为主题的综合性平台，其核心使命 是打造一个融汇智慧、链接全球资源、催化原创突破的 "枢纽（Hub）" 。他表示，发展AI不仅要追求 技术领先，更要聚焦其如何赋能基础科研、驱动产业升级、构建开放协同的创新生态。深圳河套学院将 与各合作方携手，在国家战略指引下，持续深化深港协同与国际合作，助力河套建设成为具有全球影响 力的科研高地。 创新资源加速汇聚，开放生态能级提升 论坛期间，举行了新一批国际组织与学术期刊落地河套的签约仪式，标志着河套在集聚全球高端创新资 源方面取得新的实质性进展。 转自：新华财经 12月11日，由深圳河套学院与深圳深港科技创新合作区发展有限公司联合主办的2025年度河套创新论坛 在河套科创中心成功举办。本届论坛聚焦"AI for Science Hub" 主题，采用 "1场主论坛+5场分论坛" 的形 式，汇聚政府、产业、学术、研究及投资界代表，共同探讨人工智能的前沿突破、场景应用与产学研融 合创新路径。 论坛特邀多位产业与学术领军人物，分享人工智能驱动科学发现与产业变革的最新趋势。深势科技合伙 人、高级副总裁李琴在题为《AI4S基础 ...

Investment Rating - The report rates the pharmaceutical industry as "stronger than the market" [8]. Core Insights - The pharmaceutical sector has shown a mixed performance recently, with the SW pharmaceutical index declining by 1.04%, underperforming the CSI 300 index, which decreased by 0.08% during the week of December 8 to December 14 [3]. - Key developments include positive results from Eli Lilly's GLP-1/GIP/GCG triagonist Retatrutide in its Phase III trial, achieving significant weight loss results of 26.4% and 28.7% in treatment groups compared to 2.1% in the placebo group [3]. - Wave Life Science's siRNA candidate WVE-007 demonstrated promising results in its Phase I trial, showing a 9.4% reduction in visceral fat and a 4.5% decrease in total body fat after 12 weeks, indicating a competitive edge in obesity treatment [3]. Summary by Sections Industry Performance - The pharmaceutical sector's performance has been volatile, with various sub-sectors showing differing results. CXO and innovative drugs have seen gains, while offline pharmacies and drug distribution have struggled [3]. Key Developments - Eli Lilly's Retatrutide trial results indicate a strong potential for weight loss treatment, with safety profiles consistent with other GLP-1 receptor agonists [3]. - WVE-007's mechanism of action offers a unique advantage in fat reduction while preserving muscle mass, with a potential for infrequent dosing [3]. Investment Opportunities - The report highlights the trend of Chinese innovative drug companies expanding globally, with a focus on ADCs, bispecific antibodies, small nucleic acids, and weight loss drugs as key investment areas for 2026 [3]. - Companies such as InnoCare Pharma, WuXi AppTec, and others are noted as potential investment targets due to their promising developments [3].

Core Insights - The Chinese innovative drug industry has transitioned from "importing and imitating" to "innovative output" with a significant increase in the number of approved innovative drugs and a growing focus on international markets [1][2]. Group 1: Industry Trends - The number of approved innovative drugs in China has increased significantly, with 48 new drugs expected to be approved in 2024, more than five times the number in 2018, and a total of 63 approved as of October this year [1]. - The number of new drugs under research in China ranks second globally, indicating a robust pipeline for future innovations [1]. - The "outbound" model for Chinese innovative drugs is evolving from primarily external licensing to a more diversified approach that includes "borrowing, buying, and building" [2][7]. Group 2: Factors Driving Growth - The rapid growth in innovative drugs is attributed to long-term commitment to research and development, competitive pressures, and supportive policies that have accelerated the drug approval process [3][4]. - The approval process for new drugs has significantly shortened, with the time from clinical application to market approval reduced from several years to approximately 60 working days under current policies [4]. - The integration of innovative drugs into insurance coverage has also accelerated, with the time from approval to inclusion in the insurance catalog reduced from around five years to about one year [4]. Group 3: Market Opportunities - The expiration of patents for major products from leading multinational pharmaceutical companies by 2030 presents an opportunity for Chinese innovative drugs, particularly in oncology and immunotherapy [5]. - The overseas market for innovative drugs offers significantly higher returns, with some products priced up to ten times higher than in the domestic market [5][8]. - The establishment of new companies overseas for the development and commercialization of innovative drugs is becoming a common strategy among Chinese firms, allowing them to share in future capital gains [8]. Group 4: Technological Advancements - The use of artificial intelligence in drug discovery is enhancing the efficiency of research, allowing companies to screen vast databases of compounds in a fraction of the time previously required [5][6]. - The expectation for the innovation cycle in drug development is changing, with the traditional "three tens" law (one billion dollars, ten years, and a ten percent success rate) being challenged by new technologies and methodologies [6]. Group 5: Supportive Policies and Ecosystem - Local governments are increasingly focusing on building supportive ecosystems for the biopharmaceutical industry, with initiatives aimed at funding, talent cultivation, and technological advancement [9]. - The establishment of comprehensive support policies is crucial for fostering innovation and ensuring the long-term sustainability of the industry [11].

Industry Investment Rating - The industry investment rating is "Outperform the Market" and is maintained [2]. Core Insights - The report emphasizes the potential of KT-621 (STAT6 PROTAC) as an oral alternative to Dupilumab (Dupi), highlighting its efficacy and safety in treating atopic dermatitis (AD) [6][15]. - The report suggests that the demand for oral therapies in the autoimmune sector is expected to grow, driven by the need for new molecular entities (NME) that can match existing therapies in efficacy and safety [6][25]. - The report identifies key companies to watch in the domestic market, including 康诺亚, 先声药业, 益方生物, and 海思科, which are positioned to benefit from this trend [26]. Summary by Sections Industry Overview - The closing index for the industry is 8280.55, with a 52-week high of 9323.49 and a low of 6764.34 [2]. Market Performance - In the week of December 8 to December 12, 2025, the A-share pharmaceutical and biotechnology sector fell by 1.04%, underperforming the CSI 300 index by 0.96 percentage points and the ChiNext index by 3.78 percentage points [7][45]. - The report ranks the pharmaceutical sector 17th among 31 first-level sub-industries in terms of weekly performance [7]. Recent Trends 1. **Innovative Drugs**: The report expresses optimism about the long-term trends in innovative drugs, noting that China's innovative drug industry has developed the capability to compete globally. The report highlights ongoing collaborations with multinational corporations (MNCs) as a sign of recognition of domestic companies' R&D capabilities [8][29]. 2. **Medical Devices**: The report indicates a slight decrease in funding for innovative drugs, with some capital shifting towards the medical device sector, which is expected to see improved performance [8][37]. 3. **Traditional Chinese Medicine**: The report notes that traditional Chinese medicine is under pressure but highlights potential benefits from basic drug policies and innovation [9][40]. Investment Recommendations - The report recommends focusing on companies that are well-positioned in the innovative drug space, such as 信达生物, 康方生物, and 科伦博泰生物, among others [29][30]. - For the medical device sector, companies like 迈瑞医疗 and 开立医疗 are highlighted as beneficiaries of the improving market conditions [37][38]. - In the traditional Chinese medicine sector, companies like 佐力药业 and 方盛制药 are noted for their potential to benefit from policy changes and market recovery [40][41]. Clinical Data Insights - KT-621's phase 1b clinical trial data shows comparable efficacy to Dupi, with significant reductions in biomarkers and clinical scores for atopic dermatitis [18][24]. - The safety profile of KT-621 is reported to be excellent, with no serious adverse events noted during the trial [25]. Conclusion - The report concludes that KT-621 has the potential to become a leading oral therapy in the autoimmune market, with strong backing from clinical data and market trends [25][26].

Core Insights - The pharmaceutical industry is experiencing a surge in innovative products, with clear domestic demand and significant potential for international expansion [4][14][25] - Investment opportunities are concentrated in innovative drugs and their supply chains, with a notable performance from CRO/CMO and chemical pharmaceuticals [9][15][17] - The report emphasizes the importance of innovation as the primary solution to industry challenges, driven by stable demand and supportive policies [26][32][41] Industry Overview - The pharmaceutical sector has faced revenue declines, with a 0.9% year-on-year decrease in revenue for the first three quarters of 2025, and net profit down by 2.2% [15][16] - The innovative drug sector has outperformed, with CRO/CMO and chemical pharmaceuticals showing net profit growth of 31.0% and 16.6% respectively [17][18] - The overall market is characterized by low fund holdings and historical valuation bottoms, indicating high investment value [20][25] Demand and Payment Dynamics - The demand for healthcare services is steadily increasing, with a projected 5% growth in total medical visits and hospital admissions in 2024 [26][28] - The aging population is expected to drive long-term demand, with 220 million people aged 65 and above by 2050 [28][30] - The medical insurance fund's income growth has outpaced expenditure growth, leading to a significant increase in fund reserves [32][36] Financing and Market Trends - The IPO market for healthcare has rebounded, with 28 IPOs in the first three quarters of 2025, a 100% increase from the previous year [42][43] - License-out transactions have surged, with transaction numbers increasing by 41% and total amounts reaching $92 billion, indicating a robust market for innovative drug licensing [48][50] - The number of IND applications and new clinical trials for innovative drugs has been steadily increasing, with a notable rise in NDA approvals [53][57] Technological Advancements - The report highlights the emergence of new technologies such as ADC and small nucleic acids, with domestic companies leading in these areas [60] - The focus on dual antibodies and GLP-1 drugs is expected to drive significant growth, with multiple development directions emerging [9][60] - The report notes that domestic companies are increasingly recognized for their innovative capabilities, particularly in the ADC space [60]

Investment Rating - The report maintains a "Buy" rating for the small nucleic acid sector, anticipating significant catalysts by 2026 [5]. Core Views - The report emphasizes three main investment themes for 2026: innovation, international expansion, and turnaround opportunities. It suggests focusing on innovative drugs, biotech companies that have gone global, and supply chain strategies [2][21]. - The small nucleic acid therapy market is expected to experience substantial growth, with FDA-approved drugs like Inclisiran and Vutrisiran projected to reach sales of $754 million and $971 million respectively by 2024 [3][16]. Summary by Sections 1. Small Nucleic Acid Market Outlook - The report highlights the commercial growth potential of small nucleic acid therapies, with significant sales forecasts for drugs like Inclisiran and Vutrisiran, and a projected market size of $30 billion for Novartis's xRNA therapies [3][16]. - The business development (BD) trend for siRNA therapies is improving, with notable deals such as a $4.165 billion agreement with Novartis [3][20]. - Clinical catalysts are expected, with Arrowhead's ARO-DIMER-PA set to announce trial results in H2 2026 [4][20]. - Increased capital recognition is noted, with companies like Rebio Biotech preparing for IPOs, indicating a positive market sentiment [4][20]. 2. Market Review and Trends - The report reviews the recent performance of the pharmaceutical sector, noting a 1.04% decline in the A-share pharmaceutical index, underperforming compared to the ChiNext and CSI 300 indices [24][28]. - The overall trading volume in the pharmaceutical sector was 423.35 billion yuan, accounting for 4.38% of the total market, below the historical average of 7.13% [43][24]. - The report identifies the best-performing sub-sector as medical services II, while the worst was pharmaceutical commerce II [35][38]. 3. Investment Recommendations - The report recommends focusing on high-quality siRNA companies in China, such as Frontier Biotech, Yuyuan Pharmaceutical, and others, as they are positioned for rapid development in the small nucleic acid space [7][21]. - It suggests monitoring the clinical progress of various siRNA drugs in development, particularly those targeting metabolic diseases [22][21].

Core Viewpoint - Maiwei Biotech, a company listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board in 2022, has grown into a billion-dollar enterprise with 15 key products in various stages of clinical development and a research team of nearly 400 people [1] Group 1: Company Overview - Maiwei Biotech has developed two first-in-class drugs, positioning itself among the top tier of the global biopharmaceutical industry [1] - The company has not yet achieved profitability but has effectively addressed critical pain points in research and development [1] Group 2: Industry Context - A total of 22 biopharmaceutical companies, including Maiwei Biotech, have adopted the fifth set of listing standards on the Sci-Tech Innovation Board, with cumulative R&D investments exceeding 70 billion yuan over the past three years [1] - The Sci-Tech Innovation Board is facilitating significant R&D investments from innovative drug companies, which are substantially higher than the average level in the sector [1] - Through institutional innovation, capital injection, and supportive measures, the Sci-Tech Innovation Board is helping biopharmaceutical companies overcome challenges related to long R&D cycles, high investment costs, and slow profitability, enabling a leap from R&D to commercialization and from local to global markets [1]

| 议案二、关于修订部分公司治理制度的议案 8 | | --- | 迈威（上海）生物科技股份有限公司 2025 年第三次临时股东大会会议资料 2025 年 12 月 迈威（上海）生物科技股份有限公司 2025 年第三次临时股东大会会议须知 为了维护全体股东的合法权益，保证股东在迈威（上海）生物科技股份有 限公司（以下简称"公司"）依法行使股东权利，确保 2025 年第三次临时股东 大会会议的正常秩序和议事效率，根据《中华人民共和国公司法》（以下简称 "《公司法》"）《中华人民共和国证券法》（以下简称"《证券法》"）、 中国证券监督管理委员会（以下简称"中国证监会"）《上市公司股东会规则》 以及《迈威（上海）生物科技股份有限公司公司章程》（以下简称"《公司章 程》"）《迈威（上海）生物科技股份有限公司股东大会议事规则》等有关规 定，特制定本须知，请全体出席股东大会的人员自觉遵守。 一、 为确认出席大会的股东或代理人或其他出席者的出席资格，会议工作 人员将对出席会议者的身份进行必要的核对工作，请被核对者予以配合。 二、 经公司审核后符合参加本次股东大会条件的股东（含股东代理人）、 董事、监事、高级管理人员及其他出 ...

迈威（上海）生物科技股份有限公司 2025 年第三次临时股东大会会议资料 2025 年 12 月 | 议案二、关于修订部分公司治理制度的议案 8 | | --- | 迈威（上海）生物科技股份有限公司 2025 年第三次临时股东大会会议须知 为了维护全体股东的合法权益，保证股东在迈威（上海）生物科技股份有 限公司（以下简称"公司"）依法行使股东权利，确保 2025 年第三次临时股东 大会会议的正常秩序和议事效率，根据《中华人民共和国公司法》（以下简称 "《公司法》"）《中华人民共和国证券法》（以下简称"《证券法》"）、 中国证券监督管理委员会（以下简称"中国证监会"）《上市公司股东会规则》 以及《迈威（上海）生物科技股份有限公司公司章程》（以下简称"《公司章 程》"）《迈威（上海）生物科技股份有限公司股东大会议事规则》等有关规 定，特制定本须知，请全体出席股东大会的人员自觉遵守。 一、 为确认出席大会的股东或代理人或其他出席者的出席资格，会议工作 人员将对出席会议者的身份进行必要的核对工作，请被核对者予以配合。 二、 经公司审核后符合参加本次股东大会条件的股东（含股东代理人）、 董事、监事、高级管理人员及其他出 ...